Sabry, N.M.; Naguib, T.M.; Kabel, A.M.; Khafagy, E.-S.; Arab, H.H.; Almorsy, W.A.
Ameliorative Potential of L-Alanyl L-Glutamine Dipeptide in Colon Cancer Patients Receiving Modified FOLFOX-6 Regarding the Incidence of Diarrhea, the Treatment Response, and Patients’ Survival: A Randomized Controlled Trial. Medicina 2022, 58, 394.
https://doi.org/10.3390/medicina58030394
AMA Style
Sabry NM, Naguib TM, Kabel AM, Khafagy E-S, Arab HH, Almorsy WA.
Ameliorative Potential of L-Alanyl L-Glutamine Dipeptide in Colon Cancer Patients Receiving Modified FOLFOX-6 Regarding the Incidence of Diarrhea, the Treatment Response, and Patients’ Survival: A Randomized Controlled Trial. Medicina. 2022; 58(3):394.
https://doi.org/10.3390/medicina58030394
Chicago/Turabian Style
Sabry, Nesreen M., Tamer M. Naguib, Ahmed M. Kabel, El-Sayed Khafagy, Hany H. Arab, and Walid A. Almorsy.
2022. "Ameliorative Potential of L-Alanyl L-Glutamine Dipeptide in Colon Cancer Patients Receiving Modified FOLFOX-6 Regarding the Incidence of Diarrhea, the Treatment Response, and Patients’ Survival: A Randomized Controlled Trial" Medicina 58, no. 3: 394.
https://doi.org/10.3390/medicina58030394
APA Style
Sabry, N. M., Naguib, T. M., Kabel, A. M., Khafagy, E.-S., Arab, H. H., & Almorsy, W. A.
(2022). Ameliorative Potential of L-Alanyl L-Glutamine Dipeptide in Colon Cancer Patients Receiving Modified FOLFOX-6 Regarding the Incidence of Diarrhea, the Treatment Response, and Patients’ Survival: A Randomized Controlled Trial. Medicina, 58(3), 394.
https://doi.org/10.3390/medicina58030394
